Compare Biogen Inc (BIIB) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Occidental Petroleum Corporation — how do they compare? Biogen Inc trades at $190.98 (market cap $28.34B), while Occidental Petroleum Corporation trades at $53.87 (market cap $54.28B). The key difference: Occidental Petroleum Corporation is the larger of the two by market cap, and Occidental Petroleum Corporation pays a 1.91% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | OXY | |
|---|---|---|
Market Cap | $28.34B | $54.28B |
Sector | Health | Energy |
52-Week High | $216.63 | $66.24 |
52-Week Low | $122.68 | $38.92 |
Enterprise Value | $30.62B | $75.36B |
Dividend Yield | — | 1.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Occidental Petroleum (OXY) trades at $54.81, up 3.63% with bullish technical signals and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust profitability with 22.42% net income margin and 14.04% ROE, though revenue has declined from $36.6B in 2022 to $21.6B in 2025. Analyst consensus is positive with 50% buy ratings and $66.14 price target, while recent news highlights operational improvements and geopolitical tailwinds from higher oil prices.
OXY presents a compelling investment case with earnings outperformance, debt reduction progress, and favorable oil price environment, but faces risks from commodity volatility and execution challenges in carbon capture initiatives. The stock's current valuation at 74x P/E requires sustained earnings growth to justify further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
